Search Type: drug or dietary supplement name
Search Term: simvastatin (ZOCOR)


Drug Profiles | Worst Pills, Best Pills Newsletter Articles | Additional Information from Public Citizen | Health Letter Articles

Drug and Dietary Supplement Profiles

A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.
Search results below include drug profiles where your selected drug is a secondary subject of discussion

Worst Pills, Best Pills Newsletter Articles

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a secondary subject of discussion

Additional Information from Public Citizen

Search results below include Additional Information from Public Citizen where your selected drug is a secondary subject of discussion
  • [hide all summaries]
    Allowing patients to obtain certain drugs on the basis of counseling by a pharmacist but without a doctor’s prescription is a bad idea, Public Citizen told the Food and Drug Administration (FDA) today at a public hearing.
  • [hide all summaries]
    Crestor (rosuvastatin) has 2.8 times the rate of rhabdomyolysis of the second most toxic statin, analysis shows
  • [hide all summaries]
    Letter to FDA Renewing Call for Crestor to Be Removed From Market. Rate of Kidney Damage in Crestor Patients Is 75 Times Higher Than in Patients Taking Other Cholesterol Drugs (HRG Publication #1710)

Health Letter Articles

Search results below include Health Letter Articles where your selected drug is a secondary subject of discussion
  • Drug Safety Withdrawals: Who is Responsible for Notifying Patients? [hide all summaries]
    (December 2002)
    The following editorial, by Health Letter Editor Dr. Sidney Wolfe, appeared in the December issue of Pharmacoepidemiology and Drug Safety. Ultimately, the cost for such notification should be borne by the pharmaceutical company making the dangerous drug. Pharmacists and/or physicians, if the latter have record access, should be reimbursed for doing the company’s work. In addition, the FDA should be given new legislative authority to impose mandatory drug recalls with an enforceable withdrawal schedule governing the level and rapidity of recall and patient notification.

SHOW primary search results for simvastatin (ZOCOR)